Patrick Y Wen

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma
    Patrick Y Wen
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Shields Warren 430 D, Boston, MA 02115, USA
    Neuro Oncol 13:437-46. 2011
  2. pmc Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults
    Santosh Kesari
    Center for Neuro Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Neuro Oncol 9:354-63. 2007
  3. pmc Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)
    Patrick Y Wen
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, SW430D, 44 Binney St, Boston, MA 02115, USA
    Neuro Oncol 11:853-60. 2009
  4. doi request reprint Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide
    Elizabeth R Gerstner
    Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
    J Neurooncol 103:325-32. 2011
  5. doi request reprint Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma
    Jan Drappatz
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 78:85-90. 2010
  6. doi request reprint A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma
    David A Reardon
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    Clin Cancer Res 19:900-8. 2013
  7. doi request reprint Phase II study of protracted daily temozolomide for low-grade gliomas in adults
    Santosh Kesari
    Dana Farber Brigham and Women s Cancer Center, Center for Neuro Oncology, Boston, MA 02115, USA
    Clin Cancer Res 15:330-7. 2009
  8. pmc Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
    Tracy T Batchelor
    Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 28:2817-23. 2010
  9. pmc Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
    Eudocia C Quant
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Dana Farber Brigham and Women s Hospital, Boston, MA, USA
    Neuro Oncol 11:550-5. 2009
  10. pmc A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients
    A Gregory Sorensen
    A A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Res 69:5296-300. 2009

Detail Information

Publications85

  1. pmc A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma
    Patrick Y Wen
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Shields Warren 430 D, Boston, MA 02115, USA
    Neuro Oncol 13:437-46. 2011
    ..05- and 1.12-fold, respectively, from baseline during AMG 102 treatment. AMG 102 monotherapy at doses up to 20 mg/kg was not associated with significant antitumor activity in heavily pretreated patients with recurrent GBM...
  2. pmc Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults
    Santosh Kesari
    Center for Neuro Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Neuro Oncol 9:354-63. 2007
    ..While metronomic chemotherapy may not be useful in patients with advanced disease, further studies using metronomic chemotherapy combined with more potent antiangiogenic agents in patients with less advanced disease may be warranted...
  3. pmc Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)
    Patrick Y Wen
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, SW430D, 44 Binney St, Boston, MA 02115, USA
    Neuro Oncol 11:853-60. 2009
    ..Single-agent imatinib was well tolerated but had no significant activity in recurrent meningiomas. Trough plasma concentrations of imatinib exceeded those associated with imatinib activity in chronic myelogenous leukemia...
  4. doi request reprint Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide
    Elizabeth R Gerstner
    Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
    J Neurooncol 103:325-32. 2011
    ..Vatalanib was well tolerated and this study demonstrates the safety of oral small molecule inhibitors in newly diagnosed GBM patients. Blood biomarkers may be useful as pharmacodynamic markers of response to anti-angiogenic therapies...
  5. doi request reprint Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma
    Jan Drappatz
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 78:85-90. 2010
    ..We conducted a Phase I study of vandetanib, an inhibitor of vascular endothelial growth factor receptor 2 and epidermal growth factor receptor, in patients with newly diagnosed GBM combined with RT and temozolomide (TMZ)...
  6. doi request reprint A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma
    David A Reardon
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    Clin Cancer Res 19:900-8. 2013
    ..We hypothesized that patients with recurrent glioblastoma would exhibit differential antitumor benefit based on tumor PTEN/EGFRvIII status when treated with the antiangiogenic agent pazopanib and the ErbB inhibitor lapatinib...
  7. doi request reprint Phase II study of protracted daily temozolomide for low-grade gliomas in adults
    Santosh Kesari
    Dana Farber Brigham and Women s Cancer Center, Center for Neuro Oncology, Boston, MA 02115, USA
    Clin Cancer Res 15:330-7. 2009
    ..Protracted treatment with temozolomide potentially overcomes MGMT resistance and improves outcome. We conducted a phase II study of protracted daily temozolomide in adults with low-grade gliomas...
  8. pmc Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
    Tracy T Batchelor
    Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 28:2817-23. 2010
    ..Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF). We performed a phase II study of cediranib in patients with recurrent glioblastoma...
  9. pmc Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
    Eudocia C Quant
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Dana Farber Brigham and Women s Hospital, Boston, MA, USA
    Neuro Oncol 11:550-5. 2009
    ..Those patients with malignant gliomas who progressed despite a bevacizumab-containing regimen rarely responded to the second bevacizumab-containing chemotherapeutic regimen. In such patients, alternate therapies should be considered...
  10. pmc A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients
    A Gregory Sorensen
    A A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Res 69:5296-300. 2009
    ..54; P = 0.004) and progression-free survival (rho = 0.6; P = 0.001). The vascular normalization index described here should be validated in randomized clinical trials...
  11. ncbi request reprint Medical management of brain tumor patients
    Jan Drappatz
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Neurol Clin 25:1035-71, ix. 2007
    ..Effective medical management results in decreased morbidity and mortality and improved quality of life for affected patients...
  12. pmc Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma
    Andrew D Norden
    Center for Neuro Oncology, Dana Farber Cancer Institute, 44 Binney St SW430B, Boston, MA 02115, USA
    J Neurooncol 96:211-7. 2010
    ..The role of EGFR inhibitors in meningiomas is unclear. Evaluation of multi-targeted inhibitors and EGFR inhibitors in combination with other targeted molecular agents may be warranted...
  13. doi request reprint An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    J Neurooncol 92:149-55. 2009
    ..If this conclusion proves correct, progression-free survival may be an inappropriate endpoint for phase II trials of anti-angiogenic therapies...
  14. pmc Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib
    Elizabeth R Gerstner
    Departments of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Neuro Oncol 12:466-72. 2010
    ..ADC maps can be used to suggest regions of infiltrative tumor cells with anti-VEGF therapy and should be validated in future studies...
  15. doi request reprint A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme
    Jan Drappatz
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 73:222-7. 2009
    ....
  16. doi request reprint Phase I study of GRN1005 in recurrent malignant glioma
    Jan Drappatz
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Clin Cancer Res 19:1567-76. 2013
    ..Tumor extracted from patients undergoing surgery following administration of GRN1005 was analyzed to determine whether therapeutic concentrations of GRN1005 were achieved...
  17. pmc Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults
    Santosh Kesari
    Dana Farber Brigham and Women s Cancer Center, Center for Neuro Oncology, 44 Binney St, SW430D, Boston, MA 02115, USA
    Neuro Oncol 10:300-8. 2008
    ..07) and PFS (p=0.09). The addition of celecoxib and thalidomide to adjuvant temozolomide was well tolerated but did not meet the primary end point of improvement of 4-month PFS from study enrollment...
  18. pmc Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02
    Eudocia Q Lee
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts 02215, USA
    Neuro Oncol 14:1511-8. 2012
    ..Minimal activity in recurrent glioblastoma multiforme was seen at the MTD of the 2 combined agents...
  19. doi request reprint Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03
    Eudocia Q Lee
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 18:6032-9. 2012
    ..A phase I, dose-finding study of vorinostat in combination with temozolomide (TMZ) was conducted to determine the maximum tolerated dose (MTD), safety, and pharmacokinetics in patients with high-grade glioma (HGG)...
  20. doi request reprint Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients
    Andrew D Norden
    Center for Neuro Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    J Neurooncol 106:121-5. 2012
    ..03 and 0.02, respectively). Anticoagulant use during BVZ therapy may increase the risk of hemorrhage in glioma patients, although it is generally well tolerated...
  21. doi request reprint Antiangiogenic strategies for treatment of malignant gliomas
    Andrew S Chi
    Stephen E and Catherine Pappas Center for Neuro Oncology, Dept of Neurol, Div of Hematol, and Oncol, Massachusetts General Hosp, Cancer Ctr, Boston, MA 02115 Dana Farber Harvard Cancer Ctr, Brigham and Women s Hosp, Boston, MA 02115 Harvard Med School, Brigham and Women s Hosp, Boston, MA 02115, USA
    Neurotherapeutics 6:513-26. 2009
    ....
  22. doi request reprint Antiangiogenic therapy in malignant gliomas
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Curr Opin Oncol 20:652-61. 2008
    ..This article reviews the rationale for targeting angiogenesis in malignant gliomas, summarizes relevant clinical trial results, and discusses promising avenues of investigation in antiangiogenic therapy...
  23. doi request reprint Update on bevacizumab and other angiogenesis inhibitors for brain cancer
    Mikael L Rinne
    Dana Farber Brigham and Women s Cancer Center, Center for Neuro Oncology, Boston, MA, USA
    Expert Opin Emerg Drugs 18:137-53. 2013
    ..Anti-angiogenic therapy has been a major clinical research focus in neuro-oncology over the past 5 years...
  24. pmc Prospective, high-throughput molecular profiling of human gliomas
    Andrew S Chi
    Department of Neurology, Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    J Neurooncol 110:89-98. 2012
    ....
  25. doi request reprint Outcomes after discontinuation of antiepileptic drugs after surgery in patients with low grade brain tumors and meningiomas
    Rohit R Das
    Department of Neurology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Neurooncol 107:565-70. 2012
    ..Although clinicians are able to identify patients at high risk for postoperative seizures, treatment with AEDs is ineffective in many patients...
  26. doi request reprint Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 144:895-903. 2009
    ..Bortezomib-associated peripheral neuropathy is manageable and reversible in most patients with relapsed myeloma. Dose modification using a specific guideline improves peripheral neuropathy management without adversely affecting outcome...
  27. doi request reprint Novel anti-angiogenic therapies for malignant gliomas
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Lancet Neurol 7:1152-60. 2008
    ..Normalisation of dilated and leaky tumour vasculature might also enable anti-angiogenic therapy to increase the efficacy of radiation therapy and cytotoxic chemotherapy...
  28. pmc Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy
    Paul G Richardson
    Dana Farber Cancer Institute, 44 Binney St, Dana 1B02, Boston, MA 02115, USA
    J Clin Oncol 27:3518-25. 2009
    ..Baseline myeloma-associated neuropathy seems more common than previously reported, and bortezomib-associated neuropathy, although a common toxicity, is reversible in most patients...
  29. pmc Morphological characteristics of brain tumors causing seizures
    Jong Woo Lee
    Department of Neurology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Arch Neurol 67:336-42. 2010
    ..To quantify size and localization differences between tumors presenting with seizures vs nonseizure neurological symptoms...
  30. doi request reprint Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas
    Deviney Chaponis
    Department of Pediatric Hematology Oncology, Dana Farber Cancer Institute and Children s Hospital Boston, Boston, MA, USA
    J Neurooncol 104:179-89. 2011
    ..These data support the continued research of high grade glioma treatment combinations of farnesyl transferase inhibitors, temozolomide, and radiation therapy...
  31. pmc Colon perforation during antiangiogenic therapy for malignant glioma
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Neuro Oncol 11:92-5. 2009
    ..Because GI perforation is a life-threatening yet treatable complication, neurooncologists must have a low threshold to consider it in patients on antiangiogenic drug therapy who present with abdominal pain and other GI complaints...
  32. doi request reprint Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression
    Elizabeth R Gerstner
    Department of Neurology, Division of Neuro Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston, 02114 MA, USA
    J Neurooncol 94:97-101. 2009
    ..Presence of psPD, independent of treatment, was associated with prolonged progression-free survival (P = 0.05) but not OS. psPD may be more common in combination therapy but most likely by a small margin...
  33. pmc Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape
    Emmanuelle di Tomaso
    Department of Radiation Oncology, Massachusetts General Hospital and Massachusetts Institute of Technology, Boston, Massachusetts 02114, USA
    Cancer Res 71:19-28. 2011
    ....
  34. doi request reprint Medical therapies for meningiomas
    Patrick Y Wen
    Center for Neuro Oncology, Department of Medical Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, MA 02115, USA
    J Neurooncol 99:365-78. 2010
    ....
  35. ncbi request reprint Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide
    Michelle L Monje
    Department of Neurology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Neurooncol 84:179-83. 2007
    ..Radiation-induced high-grade gliomas are a rare but serious late complication of radiotherapy. We report a patient with radiation-induced cerebellar high-grade glioma who had a durable response to temozolomide...
  36. pmc AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
    Tracy T Batchelor
    Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Cancer Cell 11:83-95. 2007
    ..Our study provides insight into different mechanisms of action of this class of drugs in recurrent glioblastoma patients and suggests that the timing of combination therapy may be critical for optimizing activity against this tumor...
  37. pmc Longitudinal MRI evidence for decreased survival among periventricular glioblastoma
    Geoffrey S Young
    Department of Radiology, Division of Neuroradiology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Neurooncol 104:261-9. 2011
    ..These results suggest that GBMs in close proximity to the ependymal surface of the ventricles convey a worse prognosis-an observation that may be useful for stratifying treatment...
  38. ncbi request reprint Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment
    Patrick Y Wen
    Harvard Medical School, Dana Farber Brigham and Women s Cancer Center, SW430D, Boston, MA 02115, USA
    Expert Rev Anticancer Ther 6:733-54. 2006
    ..In this article, the current status of targeted molecular agents for malignant gliomas will be reviewed and strategies to improve their effectiveness will be discussed...
  39. doi request reprint Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group
    Patrick Y Wen
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, SW430D, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 28:1963-72. 2010
    ..In this proposal, we present the recommendations for updated response criteria for high-grade gliomas...
  40. doi request reprint Antiangiogenic therapies for high-grade glioma
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Nat Rev Neurol 5:610-20. 2009
    ..The international Response Assessment in Neuro-Oncology Working Group has developed consensus treatment response criteria for HGG that account for the complex effects of antiangiogenic drugs...
  41. doi request reprint Current and future directions for Phase II trials in high-grade glioma
    Brian M Alexander
    Department of Radiation Oncology, Dana Farber Brigham and Women s Cancer Center, Harvard Medical School, 75 Francis Street, ASB1 L2, Boston, MA 02115, USA
    Expert Rev Neurother 13:369-87. 2013
    ..Several novel agents, multi-targeted agents and combination therapies are now in clinical trials for HGG and several more strategies are being pursued...
  42. doi request reprint Enhancing radiation therapy for patients with glioblastoma
    Brian M Alexander
    Department of Radiation Oncology, Dana Farber Brigham and Women s Cancer Center, 75 Francis Street, ASB1 L2, Boston, MA 02115, USA
    Expert Rev Anticancer Ther 13:569-81. 2013
    ..As such, there is much interest in elucidating the mechanisms of resistance to radiation therapy and in developing novel approaches to overcoming this treatment resistance...
  43. pmc Bayesian adaptive randomized trial design for patients with recurrent glioblastoma
    Lorenzo Trippa
    Dana Farber Cancer Institute, Harvard School of Public Health and Dana Farber Brigham and Women s Cancer Center, Boston, MA 02215, USA
    J Clin Oncol 30:3258-63. 2012
    ..To evaluate whether the use of Bayesian adaptive randomized (AR) designs in clinical trials for glioblastoma is feasible and would allow for more efficient trials...
  44. pmc Current clinical development of PI3K pathway inhibitors in glioblastoma
    Patrick Y Wen
    Center for Neuro Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Neuro Oncol 14:819-29. 2012
    ....
  45. doi request reprint Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial
    David A Reardon
    Center for Neuro Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue SW G460F, Boston, MA 02215, USA
    Cancer Chemother Pharmacol 69:849-60. 2012
    ..The primary objective of the study was to determine the maximum tolerated dose (MTD) of ridaforolimus...
  46. ncbi request reprint Inhibition of angiogenesis and invasion in malignant gliomas
    Andrew Chi
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, SW430D, 44 Binney Street, Boston, MA 02115, USA
    Expert Rev Anticancer Ther 7:1537-60. 2007
    ..Combination therapy with antiangiogenic and novel anti-invasion agents is a promising approach that may produce a synergistic antitumor effect and a survival benefit for patients with these devastating tumors...
  47. ncbi request reprint Targeted drug therapy for meningiomas
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Neurosurg Focus 23:E12. 2007
    ..Treatment with traditional chemotherapeutic agents has provided minimal benefit. In this review, the role of targeted molecular therapies for recurrent or progressive meningiomas is discussed...
  48. doi request reprint Malignant gliomas in adults
    Patrick Y Wen
    Division of Neuro Oncology, Department of Neurology, Dana Farber corrected Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 359:492-507. 2008
  49. ncbi request reprint Advances in meningioma therapy
    Andrew D Norden
    Center for Neuro Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Curr Neurol Neurosci Rep 9:231-40. 2009
    ..Angiogenesis inhibitors, agents that target fundamental cell signaling pathways, somatostatin analogues, and a variety of other molecular treatments appear promising...
  50. doi request reprint Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Lancet Oncol 14:e407-16. 2013
    ..In this report, the second in a two-part series, we review clinical trials of brain metastases in relation to measures of clinical benefit and provide a framework for the design and conduct of future trials. ..
  51. pmc Phase 2 study of dose-intense temozolomide in recurrent glioblastoma
    Andrew D Norden
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 450 Brookline Ave, Boston, MA 02215, USA
    Neuro Oncol 15:930-5. 2013
    ..Resistance to temozolomide is partially mediated by O(6)-methylguanine-DNA methyltransferase (MGMT). Because MGMT may be depleted by prolonged temozolomide administration, dose-intense schedules may overcome resistance...
  52. doi request reprint Central nervous system complications of cancer therapy
    Mikael L Rinne
    Center for Neuro Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Support Oncol 10:133-41. 2012
    ..This review highlights the CNS complications that result from radiation, chemotherapy, and novel therapeutics...
  53. ncbi request reprint Cerebrospinal fluid spread of anaplastic glioma
    Ozden Narin
    Dana Farber Brigham and Women s Cancer Center, Center for Neuro Oncology, Boston, MA, USA
    J Clin Oncol 25:596-7. 2007
  54. doi request reprint Response assessment in neuro-oncology
    Eudocia C Quant
    Center for Neuro Oncology, Department of Medical Oncology, Dana Farber Brigham and Women s Cancer Center, SW430D, 44 Binney Street, Boston, MA 02115, USA
    Curr Oncol Rep 13:50-6. 2011
    ..This article reviews current response criteria for high-grade glioma, low-grade glioma, brain metastasis, meningioma, and schwannoma...
  55. ncbi request reprint Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib
    David M Jackman
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 24:4517-20. 2006
  56. doi request reprint Survival among patients with primary central nervous system lymphoma, 1973-2004
    Andrew D Norden
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 44 Binney St, Boston, MA 02115, USA
    J Neurooncol 101:487-93. 2011
    ..55 [95% CI 4.01, 5.16]). Despite treatment advances, survival among PCNSL patients in the United States remains poor. However, in the subset of PCNSL patients who are HIV-negative, survival has improved over time...
  57. ncbi request reprint Glioma therapy in adults
    Andrew D Norden
    Division of Cancer Neurology, Department of Neurology, Brigham and Women s Hospital and Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts 02115, USA
    Neurologist 12:279-92. 2006
    ..Despite recent advances, two-year survival for glioblastoma with optimal therapy is less than 30%. Even among patients with low-grade gliomas that confer a relatively good prognosis, treatment is almost never curative...
  58. doi request reprint Response assessment challenges in clinical trials of gliomas
    Patrick Y Wen
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center and Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, SW430D, 44 Binney Street, Boston, MA 02115, USA
    Curr Oncol Rep 12:68-75. 2010
    ..This review discusses challenges that have emerged in assessing response in patients with gliomas and approaches being introduced to address them...
  59. doi request reprint Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives
    David P Samuel
    Harvard Medical School, Pediatric Medical Neuro Oncology, Dana Farber Cancer Institute and Children s Hospital of Boston, Boston, MA 02115, USA
    Expert Opin Investig Drugs 18:973-83. 2009
    ....
  60. doi request reprint Response criteria for glioma
    A Gregory Sorensen
    Harvard Medical School, Boston, MA, USA
    Nat Clin Pract Oncol 5:634-44. 2008
    ....
  61. doi request reprint Treatment of recurrent high-grade gliomas
    Patrick Y Wen
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts 02115, USA
    Curr Opin Neurol 22:657-64. 2009
    ..Although therapies for patients with recurrent high-grade gliomas are limited, there has been important progress recently. This review summarizes current treatments for recurrent high-grade gliomas with an emphasis on more novel approaches...
  62. ncbi request reprint Targeted molecular therapy of malignant gliomas
    Santosh Kesari
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, MA 02115, USA
    Curr Neurol Neurosci Rep 5:186-97. 2005
    ..This review summarizes the current results with targeted molecular agents in malignant gliomas and strategies under evaluation to increase their effectiveness...
  63. doi request reprint Recurrent acute promyelocytic leukemia presenting as a sacral nerve root mass
    Santosh Kesari
    Department of Neurology, Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, MA, USA
    J Clin Oncol 26:3279-81. 2008
  64. doi request reprint Prognostic factors in adult brainstem gliomas: a multicenter, retrospective analysis of 101 cases
    Santosh Kesari
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, MA 02115, USA
    J Neurooncol 88:175-83. 2008
    ..We retrospectively evaluated the clinical, radiographic, histologic, and treatment features from 101 adults with presumed or biopsy proven BSG to determine prognostic factors...
  65. doi request reprint Therapeutic strategies for inhibiting invasion in glioblastoma
    Jan Drappatz
    Center for Neuro Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston MA 02115, USA
    Expert Rev Neurother 9:519-34. 2009
    ..Recently, there has been important progress in understanding the molecular determinants of glioma invasion and migration. This review will summarize some of the therapeutic strategies for inhibiting invasion in glioblastomas...
  66. ncbi request reprint Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
    Patrick Y Wen
    Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts, USA
    Clin Cancer Res 12:4899-907. 2006
    ..Phase II: To determine the therapeutic efficacy of imatinib...
  67. pmc Discontinuing bevacizumab in patients with glioblastoma: an ethical analysis
    Jennifer C Kesselheim
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Oncologist 16:1435-9. 2011
    ..With the increasing availability of new, modestly toxic, expensive drugs for patients with advanced cancer, questions of when to stop these drugs will become increasingly relevant...
  68. doi request reprint Epidemiology of brain metastases
    Lakshmi Nayak
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, 450 Brookline Avenue, SW 430D, Boston, MA 02215, USA
    Curr Oncol Rep 14:48-54. 2012
    ..Some patients present with no known primary cancer diagnosis. In children, brain metastases are rare; germ cell tumors, sarcomas, and neuroblastoma are the common offenders...
  69. ncbi request reprint Medical management of patients with brain tumors
    Patrick Y Wen
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital and Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, SW430D, 44 Binney Street, Boston, MA 02115, USA
    J Neurooncol 80:313-32. 2006
    ..Medications such as modafinil and methylphenidate have assumed an increasing role in the treatment of fatigue, while donepezil and memantine may be helpful with memory loss...
  70. ncbi request reprint Therapy for recurrent malignant glioma in adults
    Maciej M Mrugala
    Harvard Medical School, Center for Neuro Oncology, Dana Farber Cancer Institute, Boston, MA 02114, USA
    Expert Rev Anticancer Ther 4:759-82. 2004
    ..Standard therapy for patients with this disease will be reviewed, together with more novel approaches such as targeted molecular therapies, angiogenesis inhibitors, immunotherapies, gene therapies and intratumoral therapies...
  71. doi request reprint Novel medical therapeutics in glioblastomas, including targeted molecular therapies, current and future clinical trials
    Eudocia C Quant
    Division of Cancer Neurology, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, SW 430D, Boston, MA 02115, USA
    Neuroimaging Clin N Am 20:425-48. 2010
    ..This article reviews novel therapies for glioblastoma, with an emphasis on targeted agents...
  72. pmc Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss
    Matija Snuderl
    Pathology Service, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 2698, USA
    Clin Cancer Res 15:6430-7. 2009
    ..The purpose of this study was to evaluate the prognostic significance of polysomy of chromosomes 1 and 19 in the setting of 1p/19q codeletion...
  73. ncbi request reprint Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib
    Paul G Richardson
    Dana Farber Cancer Institute, Brigham and Women s Hospital, 44 Binney St, Dana 1B02, Boston, MA 02115, USA
    J Clin Oncol 24:3113-20. 2006
    ..To determine the frequency, characteristics, and reversibility of peripheral neuropathy from bortezomib treatment of advanced multiple myeloma...
  74. doi request reprint Emerging antiangiogenic treatments for gliomas - efficacy and safety issues
    Jörg Dietrich
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Curr Opin Neurol 21:736-44. 2008
    ..To review the rationale and recent experience of angiogenesis inhibitors in malignant gliomas and to highlight both the promise and potential complications of these agents...
  75. ncbi request reprint Non-cytotoxic drugs as potential treatments for gliomas
    Jan Drappatz
    Center for Neuro Oncology, Dana Farber Cancer Institute, Department of Neurology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Curr Opin Neurol 17:663-73. 2004
    ..This review summarizes the most recent developments in non-cytotoxic therapy for malignant gliomas, such as targeted molecular drugs, inhibitors of angiogenesis and intratumoral therapy...
  76. ncbi request reprint Brain metastases
    Andrew D Norden
    Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Curr Opin Neurol 18:654-61. 2005
    ..The management of patients with multiple metastases, poor prognostic factors, or unresectable lesions is, however, controversial. Recently published data will be reviewed...
  77. pmc Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas
    Gaurav D Shah
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Neuro Oncol 8:38-46. 2006
    ..Thus, linear methods are comparable to volumetric methods, but simpler to implement for routine clinical use and for designing clinical trials of brain tumors...
  78. ncbi request reprint Recurrent high-grade glioma
    Eudocia C Quant
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, SW430B, 44 Binney Street, Boston, MA, 02115, USA
    Curr Treat Options Neurol 12:321-33. 2010
    ....
  79. ncbi request reprint Chemotherapy and targeted molecular therapies for brain metastases
    Jan Drappatz
    Center for Neuro Oncology Dana Farber Brigham and Women s Cancer Center, and Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Expert Rev Neurother 6:1465-79. 2006
    ..In this review, the current role of chemotherapy and targeted molecular agents for brain metastases is summarized and future directions are discussed...
  80. ncbi request reprint Inhibiting kinases in malignant gliomas
    Andrew S Chi
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Shields Warren 430D, 44 Binney Street, Boston, MA 02115, USA
    Expert Opin Ther Targets 11:473-96. 2007
    ..This article reviews the important protein kinases in malignant gliomas, summarizes the existing clinical development of kinase inhibitors and discusses strategies to improve their effectiveness...
  81. ncbi request reprint Malignant gliomas
    Patrick Y Wen
    Center for Neuro Oncology, Dana Farber Cancer Institute, SW430D, 44 Binney Street, Boston, MA 02115, USA
    Curr Neurol Neurosci Rep 4:218-27. 2004
    ..Although therapy for patients with these tumors remains limited, there has been important progress recently. In this review, some of these advances are discussed, with an emphasis on targeted molecular therapies...
  82. ncbi request reprint Medical management of patients with brain tumors
    Patrick Y Wen
    Harvard Medical School, Center for Neuro Oncolgy, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Curr Opin Oncol 14:299-307. 2002
    ....
  83. ncbi request reprint Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities
    Elizabeth A Maher
    Center for Neuro Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 66:11502-13. 2006
    ..We conclude that glioblastoma is composed of at least three distinct molecular subtypes, including novel subgroups of secondary glioblastoma, which may benefit from different therapeutic strategies...
  84. ncbi request reprint Neurologic complications of cancer therapy
    Scott R Plotkin
    Department of Neurology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02446, USA
    Neurol Clin 21:279-318, x. 2003
    ....
  85. ncbi request reprint Neurologic complications of solid tumors
    Patrick Y Wen
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, 75 Francis St Boston, MA 02115, USA
    Neurol Clin 21:107-40, viii. 2003
    ..As systemic therapy improves for many of these tumors, patients are surviving longer and the incidence of neurologic complications is increasing...